Safety of Inpatient Zoledronic Acid in the Immediate Post-Fracture Setting

Autor: WuQiang Fan, Benjamin Z Leder, Michael Mannstadt, Thuan V Ly, Esteban Franco-Garcia, Marcy B Bolster

Publikováno v: The Journal of Clinical Endocrinology & Metabolism.

Context Zoledronic acid (ZA) administered during the initial hospitalization for a fragility fracture improves the osteoporosis pharmacotherapy rate. Distinguishing the safety profile of inpatient ZA (IP-ZA) in this context is crucial if this approac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a38563c53ab6266b671aaa03c6c94dd
https://doi.org/10.1210/clinem/dgad295

Romosozumab and antiresorptive treatment: the importance of treatment sequence

Autor: Felicia Cosman, David L. Kendler, Bente L. Langdahl, Benjamin Z. Leder, E. Michael Lewiecki, Akimitsu Miyauchi, Maria Rojeski, Michele McDermott, Mary K. Oates, Cassandra E. Milmont, Cesar Libanati, Serge Ferrari

Publikováno v: Cosman, F, Kendler, D L, Langdahl, B L, Leder, B Z, Lewiecki, E M, Miyauchi, A, Rojeski, M, McDermott, M, Oates, M K, Milmont, C E, Libanati, C & Ferrari, S 2022, ' Romosozumab and antiresorptive treatment : the importance of treatment sequence ', Osteoporosis International, vol. 33, no. 6, pp. 1243-1256 . https://doi.org/10.1007/s00198-021-06174-0

Summary: To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab follo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94e72c5c5eae6312e53d45028a2072b
https://doi.org/10.1007/s00198-021-06174-0

Osteoporosis Prevention and Treatment

Autor: Mary Beth Humphrey, Bita Zahedi, Amy Warriner, Sarah Morgan, Benjamin Z. Leder, Ken Saag, Elaine W. Yu

Publikováno v: A Clinician's Pearls & Myths in Rheumatology ISBN: 9783031234873

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e99440c72f6b9b60547feaed62b2dd9d
https://doi.org/10.1007/978-3-031-23488-0_41

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension

Autor: Benjamin Z. Leder, Sabashini K Ramchand, Joy N. Tsai, Natalie L David, Hang Lee, Richard Eastell

Publikováno v: Journal of Bone and Mineral Research. 36:921-930

Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high-turnover bone loss and increased fracture risk. The optimal way to prevent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65b75a6b098b30c551c36162dee2e9a
https://doi.org/10.1002/jbmr.4259

Effects of Combination Denosumab and High‐Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA‐HD HR‐pQCT Study

Autor: Sabashini K Ramchand, Joy N. Tsai, Benjamin Z. Leder, Hang Lee, Michael Bruce, Natalie L David, Mary L. Bouxsein

Publikováno v: Journal of Bone and Mineral Research. 36:41-51

In postmenopausal women at high risk of fracture, we previously reported that combined denosumab and high-dose (HD; 40 μg) teriparatide increased spine and hip bone mineral density (BMD) more than combination with standard-dose teriparatide (SD; 20

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f5308c93d7d55b7ae69c6cb8ed7726
https://doi.org/10.1002/jbmr.4161